A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib
(NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed
Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117
NHL (Non-Hodgkins Lymphoma)
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.
Back to Clinical Trials list